Managing type 2 diabetes (T2D) involves a multi-pronged approach. It relies on lifestyle changes, medications, blood sugar monitoring, and ongoing education. However, research in T2D management is ever-changing; by continuously exploring and refining these pillars of management, health care professionals can optimize health outcomes for patients with the condition.
Six abstracts presented at the American Diabetes Association 84th Scientific Sessions, held June 21 to 24 in Orlando, Florida, explored how different interventions or factors, such as diet and nutrition, medication, or comorbidities, can impact T2D management.
Click here for more of our coverage from ADA 2024.
READ MORE: Diabetes Resource Center
Don’t get left behind: Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.
References
1. Mottalib A, Hamdy O. Structured medical nutrition therapy improves glycemia, reduces percentage body fat while maintaining fat-free mass in individuals with overweight/obesity and type 2 diabetes. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 132-OR.
2. Moore J, Rutland S, Murphy J, Tarasovich M. Impact of a six-month digital health coaching program on individuals with type 2 diabetes mellitus experiencing food insecurity in rural areas. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 652-P.
3. Jang H, Sung G, Faulkner MS, Cha E. Social determinants of health and early-onset type 2 diabetes—a qualitative study. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 1849-LB.
4. Zhuang M, Zhai L, Bian Z, Lin C, Hoi K. Metformin mitigates insulin signaling variations induced by COVID-19 vaccine boosters in type 2 diabetes. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 1855-LB.
5. Ubalde SN, Khoury J, Davis J, Sen S. Type 2 diabetic medication regimen in treating depression and metabolic dysfunction–associated steatotic liver disease (MASLD) in veterans using PHQ-9 and FIB-4 scores. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 1889-LB.
6. Ray A, Paik JM, Feldman WB, Kattinakere Sreedhara S, Wexler DJ, Patorno E. dGlucose-lowering drugs and risk of COPD exacerbations in adults with type 2 diabetes. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 796-P.
